Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
We use essential cookies by default: sign-in, your choice in this banner (supstack-consent) and your language (NEXT_LOCALE). Vercel Web Analytics (cookieless page counts) and Sentry error reports (without replay) run either way. Only if you choose "Accept all" do we also create a browser ID in local storage (it ties your visits together in our site records), record error-replay diagnostics (Sentry: masked DOM snapshots, only when an error fires) and turn on load-time metrics (Vercel Speed Insights) so we can fix slow pages faster. Learn more about cookies
Clascoterone doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2011–2026 with a typical study size of 609 participants.
Based on 27 studies · 2 meta-analyses · 7 RCTs · 8,484 total participants
Study base
27 studies indexed
By outcome
Every outcome below: Too few graded studies.
Skin healthTreatment success (clear or almost clear with a 2-grade improvement) in about 20% of patients at 12 weeks versus about 8% on vehicle; comedonal lesions respond more reliably than inflammatory ones · Reduced total lesion count and acne severity in moderate-to-severe facial acne; no evidence for general skin quality outside acne · 12 weeks17 studies
17 studies
Safety profile3 studies
3 studies
Anxiety & stress2 studies
2 studies
Men's vitality1 study
1 study
Kidney & renal health1 study
1 study
Active research area
22 studies in the last 5 years · Latest meta-analysis: 2024
201120182026
1RCTCited 110×n=1,440 · large study2020
In plain English: Two identical multicentre, vehicle-controlled, double-blind phase 3 studies (CB-03-01/25 and CB-03-01/26) randomised 1440 patients aged 9 years and older with moderate or severe facial acne to clascoterone cream 1% or vehicle twice daily for 12 weeks.
Hebert A, et al. · JAMA Dermatol (2020)
The pivotal registration trials: two identical phase 3 studies, 1440 patients randomised, conducted November 2015 to April 2018.
Eligibility required 30-75 inflammatory and 30-100 noninflammatory lesions, so the result speaks to moderate-to-severe disease rather than mild acne.
Treatment success was defined as an IGA of 0 or 1 PLUS a 2-grade or greater improvement — a stricter endpoint than "improved".
2RCTCited 6×n=1,421 · large study2023
In plain English: In a pooled analysis of the two phase 3 trials restricted to patients aged 12 years and over, treatment success at week 12 was 19.9% with clascoterone versus 7.7% with vehicle.
Eichenfield L, et al. · J Drugs Dermatol (2023)
709 patients received clascoterone and 712 received vehicle in the pooled ≥12-year population.
Treatment success 19.9% vs 7.7% — a real difference, and also a reminder that four in five treated patients did NOT reach clear or almost clear at 12 weeks.
Absolute change from baseline: noninflammatory lesions -20.8 vs -11.9, inflammatory -19.7 vs -14.0, total -40.0 vs -26.1 (all P<0.0001).
3Meta-AnalysisCited 12×n=2,457 · very large study2021
In plain English: Pooling five trials (2457 patients), clascoterone increased IGA success (RR 2.87, 95% CI 2.11-3.89) and reduced noninflammatory lesions (MD -5.64), but did NOT significantly change inflammatory lesion counts (MD -1.82, 95% CI -5.06 to 1.43, P = .27).
Ibrahim O, et al. · Dermatol Ther (2021)
Five trials, 2457 patients (1357 clascoterone, 1100 placebo), overall low risk of bias.
The inflammatory-lesion result was null: MD -1.82, 95% CI -5.06 to 1.43, P = .27. The confidence interval crosses zero.
Noninflammatory (comedonal) lesions did improve: MD -5.64, 95% CI -8.41 to -2.87.
4Review2026
In plain English: Available evidence supports the use of clascoterone cream 1% and suggests potential benefits and limitations of topical spironolactone in patients with AV; however, for topical spironolactone, pharmacokinetic studies and large-scale RCTs are needed to better characterize both efficacy and safety profiles.
Del Rosso JQ, Baldwin H, Layton AM. · The Journal of clinical and aesthetic dermatology (2026)
Six clinical studies-mostly small, randomized trials-reported 193 patients treated with topical spironolactone as 5% cream, 5% gel, 2% solution, and 1% nanogel, and 1 RCT evaluated topical flutamide gel in 27 patients.
The efficacy and safety of topical spironolactone and flutamide are supported by limited data with some conflicting results; neither agent is approved by the FDA and both must be compounded extemporaneously with no supporting pharmacokinetic data.
Limitations Clinical studies of topical spironolactone are limited by the small number of patients and wide range of formulations evaluated.
5RCT2024
In plain English: The efficacy of clascoterone cream 1% for the treatment of acne vulgaris continued to increase over time for up to 12 months in patients aged 12 years or older with acne vulgaris.
Eichenfield LF, Gold LS, Han J, Hebert AA, Mazzetti A, Moro L, Squittieri N, Thiboutot D. · Journal of drugs in dermatology : JDD (2024)
Background Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged 12 years or older based on results from two identical pivotal Phase 3 trials.
The treatment success rate and most lesion count reductions following clascoterone vs placebo treatment reached statistical significance at week 12; the overall treatment success rate increased to 30.2% for facial acne after 12 months and 31.7% for truncal acne after 9 months of treatment.
Conclusions The efficacy of clascoterone cream 1% for the treatment of acne vulgaris continued to increase over time for up to 12 months in patients aged 12 years or older with acne vulgaris.
In plain English: Twice-daily treatment with clascoterone cream 1% for 2 weeks was associated with increased moisturization and maintenance of skin barrier function as assessed by corneometry and TEWL and was otherwise well tolerated.
D Draelos Z, Kyeremateng K, Squittieri N. · Journal of drugs in dermatology : JDD (2025)
This study aimed to evaluate the effects of clascoterone cream 1% on skin barrier properties in acne-prone individuals.
Methods Participants ≥18 years of age with acne-prone skin were enrolled in a single-center, split-face study and randomized to twice-daily treatment with clascoterone cream 1% (approximately 0.5 g) to the right or left side of the face for 2 weeks.
The mean ± SD corneometry reading was significantly higher for the treated vs untreated side at week 2 (131.3 ± 42.9 vs 113.9 ± 36.6; P<0.001).
In plain English: These results further support the efficacy and tolerability of clascoterone cream 1% across the spectrum of patients ≥12 years of age with acne vulgaris.  .
Libecco J, Eichenfield LF, Hebert AA, Gold LS, Cartwright M, Moro L, Sane S, Lionnet L, Shukla D, Mazzetti A, Squittieri N, Kyeremateng K. · Journal of drugs in dermatology : JDD (2026)
Clascoterone cream 1% is indicated for the topical treatment of acne vulgaris in patients ≥12 years of age based on the results of two Phase 3 trials (NCT02608450 and NCT02608476).
This post hoc analysis evaluated the efficacy and safety of clascoterone cream 1% in patient subgroups defined by age (adolescent vs adult) and sex (male vs female).
Patients ≥12 years of age with mild-to-moderate acne applied clascoterone cream 1% or vehicle twice daily for 12 weeks.
In plain English: Under maximum-use exposure for 14 days, 5 of 69 clascoterone-treated patients had an abnormal cosyntropin stimulation test at day 14, and all had normal cortisol at follow-up roughly 4 weeks later.
Eichenfield L, et al. · J Drugs Dermatol (2024)
The specific safety question for a topical antiandrogen: does it suppress the adrenal axis? Answer — mildly and reversibly, under maximum-use conditions.
5/69 abnormal at day 14: 1/20 adults, 2/22 aged 12 to <18, 2/27 aged 9 to <12. Younger patients were not exempt.
All abnormal results normalised at follow-up; no clinically relevant adverse events accompanied them.
9Review2024
In plain English: It is essential that individualized therapy, incorporating patient preferences and considering adverse effects, is emphasized for optimizing acne management.
Althwanay A, AlEdani EM, Kaur H, Kasapoglu M, Yadavalli R, Nawaz S, Nath TS. · Cureus (2024)
Retinoids, such as tretinoin and adapalene, significantly improved both lesion types (open and closed comedones).
Niacinamide, examined in a randomized controlled trial involving 41 participants, reduced sebum production.
Another study with 60 patients revealed that azelaic acid effectively reduced both inflammatory and non-inflammatory lesions.
In plain English: J Drugs Dermatol. 2024;23(6):404-409. doi:10.36849/JDD.7846.
Cantrell W, Easley L, Squittieri K. · Journal of drugs in dermatology : JDD (2024)
Topical clascoterone can be used by female and male patients 12 years of age and older.
Patients' characteristics (including age and patients with darker skin color) and preferences for the route of administration can impact treatment response and adherence, respectively.
Overall, healthcare providers must be aware of the differences among steroidal acne treatments and use shared decision-making to select the optimal therapy.
In plain English: In 363 subjects, week-12 treatment success was 8.6% for clascoterone 1% twice daily and 8.3% for 0.1% twice daily, versus 2.7% for vehicle.
Trifu V, et al. · J Drugs Dermatol (2019)
The dose-finding study that selected the 1% twice-daily regimen.
On the treatment success endpoint the dose-response was flat: 1% BID (8.6%) barely differed from 0.1% BID (8.3%) across a tenfold concentration range. Lesion counts did improve with dose.
Absolute change in inflammatory (P=0.0431) and noninflammatory (P=0.0303) lesions was significant ACROSS treatment groups, not as a clascoterone-versus-vehicle contrast.
12Review2025
In plain English: Phase 1 study findings supported low systemic absorption of clascoterone and a favorable safety profile after topical application of clascoterone cream 1%, with no evidence of irritation or sensitization.
Di Stefano AFD, Radicioni MM, Garhöfer G, Cartwright M, Müller M, Kopeloff I, Moro L, Squittieri N, Mazzetti A. · Clinical pharmacology in drug development (2025)
Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne.
Clascoterone was excreted in urine as conjugated esters at a ≤1% fraction of the administered dose.
Phase 1 study findings supported low systemic absorption of clascoterone and a favorable safety profile after topical application of clascoterone cream 1%, with no evidence of irritation or sensitization.
In plain English: Clascoterone represents a novel addition to the therapeutic armamentarium for acne vulgaris, offering a unique mechanism of action with a favorable safety profile.
Shefa S, Szwach J, Karwowska A, Wojno A, Łyko M. · Pharmaceuticals (Basel, Switzerland) (2026)
Acne vulgaris is one of the most prevalent dermatological conditions, affecting up to 85% of individuals aged 11-30 years.
Phase 3 trials and meta-analyses demonstrate that twice-daily application of clascoterone 1% cream significantly reduces inflammatory and non-inflammatory lesion counts compared to vehicle, with efficacy sustained up to 12 months of treatment.
In an exploratory pooled subgroup analysis, lesion-count reductions were greater in adults than in adolescents, whereas the adjusted between-group comparison of IGA success was not statistically significant.
No plain-language summary recorded for this citation — open the paper to read its abstract.
15Review2026
In plain English: Recognition of acne as a chronic inflammatory condition has supported the increasing use of hormonal therapies as an important treatment option in selected adolescent patients.
Torres-Zegarra C et al. · Current opinion in pediatrics (2026)
Recognition of acne as a chronic inflammatory condition has supported the increasing use of hormonal therapies as an important treatment option in selected adolescent patients.
In plain English: Treatment with Winlevi is expected to cost up to $5,899 per patient per year.
· Unknown Journal (2025)
Acne affects about 5.6 million people in Canada.
UNMET NEEDS IN ACNE VULGARIS: Patients and clinicians identified a need for access to effective and safe treatment options that improve skin clearance, prevent acne scarring and pigmentation, are nonirritating, work quickly, and improve quality of life.
HOW MUCH DOES WINLEVI COST?
17Review2025
· Unknown Journal (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
18Open-LabelCited 29×n=609 · large study2020
In plain English: Across up to 9 months of twice-daily use on face and/or trunk in 609 enrolled patients, 110 (18.1%) experienced a treatment-emergent adverse event, and the 7 serious events in 6 patients were none of them treatment related.
Eichenfield L, et al. · J Am Acad Dermatol (2020)
The long-term safety anchor: up to 9 MONTHS of continuous twice-daily use (not 12).
609 enrolled, 347 completed. 18.1% had a treatment-emergent adverse event; nasopharyngitis was the most common (n=20).
Local skin reactions occurred in 18.1% (110/607) — most commonly erythema, scaling/dryness and pruritus, most trace/minimal or mild.
19Meta-AnalysisCited 6×n=2,006 · very large study2024
In plain English: Topical clascoterone 1% twice daily reduced inflammatory (SMD -0.27) and noninflammatory (SMD -0.31) lesion counts versus placebo, while oral spironolactone 200 mg reduced TOTAL lesion count by SMD -4.46 — different outcomes, so the two figures are not directly comparable.
Abdelmaksoud A, et al. · PLoS One (2024)
Indirect comparison with oral spironolactone, the established systemic antiandrogen for acne.
The effect sizes are on different outcomes: clascoterone's -0.27/-0.31 are inflammatory and noninflammatory counts, spironolactone's -4.46 is total lesion count. Read as a potency ratio it would overstate the gap.
Clascoterone was significantly associated with 12-week treatment success versus placebo (OR 2.44, 95% CI 1.12-5.30).
20Review2025
In plain English: In addition, opportunities to improve the patient experience with spironolactone and isotretinoin are discussed.
This review provides a comprehensive summary of the latest developments in acne management, exploring a range of topical, systemic, and procedural treatments.
The mechanisms of action, pivotal trial data, and potential role in clinical practice are reviewed for emerging therapies such as 1726 nm laser, sarecycline, clascoterone, trifarotene, minocycline foam, and fixed-dose combination topicals.